← Leaderboards
Amber L Beitelshees
University Of Maryland Baltimore
$6,724,440
Attributed
$10,014,370
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2007–25$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,014,370 · 7
By mechanism
R01$8,917,558 · 3
K23$660,741 · 1
R21$431,955 · 1
M01$4,116 · 2
Top collaborators
- Simeon I Taylor10 shared
- May Montasser2 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Simeon I Taylor$9,588,026
- Edward J Weinman$4,634,345
- Norann Amir Zaghloul$1,719,991
- Gregory H Taylor$675,996
Others in their field
Top investigators on “Genetic”
- Richard A Gibbs · Baylor College Of Medicine$577,061,667
- Eric S Lander · Whitehead Institute For Biomedical Res$560,806,052
- David R. Weir · University Of Michigan At Ann Arbor$322,225,557
- Richard K. Wilson · Washington University$316,685,275
- Lawrence Corey · Fred Hutchinson Cancer Center$312,182,347
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$302,429,647
Research focus
GeneticVariantGenotypeResponseGlucosePharmaceutical PreparationsAmishGenesNon-DiabeticCardiovascular SystemProgramsDiabetes MellitusEventPharmacogenomicsDiabetic PatientMetabolicDesignCardiovascular DiseasesRecording Of Previous EventsReportingMediatingGenetic VariantAmericanPlasma
Grant awards (24)
Comparing Direct and Indirect Methods for Cascade Screening in Familial Hypercholesterolemia (FH) and Long QT Syndrome (LQTS)$696,129
R01 · FY2025 · HL · contact PI
Pharmacogenetics of the Response to a GLP1R Agonist$604,825
R01 · FY2025 · DK · contact PI
Comparing Direct and Indirect Methods for Cascade Screening in Familial Hypercholesterolemia (FH) and Long QT Syndrome (LQTS)$676,187
R01 · FY2024 · HL · contact PI
Pharmacogenetics of the Response to a GLP1R Agonist$645,147
R01 · FY2024 · DK · contact PI
Comparing Direct and Indirect Methods for Cascade Screening in Familial Hypercholesterolemia (FH) and Long QT Syndrome (LQTS)$698,695
R01 · FY2023 · HL · contact PI
Pharmacogenetics of the Response to a GLP1R Agonist$672,029
R01 · FY2023 · DK · contact PI
Comparing Direct and Indirect Methods for Cascade Screening in Familial Hypercholesterolemia (FH) and Long QT Syndrome (LQTS)$714,707
R01 · FY2022 · HL · contact PI
Pharmacogenetics of the Response to a GLP1R Agonist$672,029
R01 · FY2022 · DK
Genetics of Response to Canagliflozin$639,301
R01 · FY2022 · DK · contact PI
Genetics of Response to Canagliflozin$677,220
R01 · FY2021 · DK
Genetics of Response to Canagliflozin$682,434
R01 · FY2020 · DK
Genetics of Response to Canagliflozin$689,388
R01 · FY2019 · DK
A Community-Based Approach to Overcoming Barriers to Cascade Screening for Long QT Syndrome$235,342
R21 · FY2019 · HG · contact PI
Do vitamin D supplements protect against adverse effect of canagliflozin on bone health?$154,377
R01 · FY2019 · DK
Genetics of Response to Canagliflozin$695,090
R01 · FY2018 · DK
A Community-Based Approach to Overcoming Barriers to Cascade Screening for Long QT Syndrome$196,613
R21 · FY2018 · HG · contact PI
Uncoupling Protein Polymorphisms and Cardiometabolic Responses to Beta-Blockers$132,842
K23 · FY2012 · HL · contact PI
Uncoupling Protein Polymorphisms and Cardiometabolic Responses to Beta-Blockers$132,842
K23 · FY2011 · HL · contact PI
Uncoupling Protein Polymorphisms and Cardiometabolic Responses to Beta-Blockers$132,842
K23 · FY2010 · HL · contact PI
Uncoupling Protein Polymorphisms and Cardiometabolic Responses to Beta-Blockers$132,566
K23 · FY2009 · HL · contact PI
PATHWAY PHARMACOGENETICS AND ANGIOTENSIN RECEPTOR BLOCKER RESPONSES$3,438
M01 · FY2009 · RR · contact PI
Uncoupling Protein Polymorphisms and Cardiometabolic Responses to Beta-Blockers$101,900
K23 · FY2008 · HL · contact PI
Uncoupling Protein Polymorphisms and Cardiometabolic Responses to Beta-Blockers$27,749
K23 · FY2008 · HL · contact PI
TELMISARTAN PHARMACOGENETICS$678
M01 · FY2007 · RR · contact PI